Craig M. Crews

43.2k citations

209 papers · 32.0k indexed · 25 hit papers · h-index 90

Molecular Biology top 0.05%
Oncology top 0.05%
Hematology top 0.05%
Organic Chemistry top 0.5%
Cell Biology top 0.5%

Co-authors: Raymond L. Erikson George M. Burslem Miklós Békés David R. Langley John Hines Momar Toure Raymond J. Deshaies Kathleen M. Sakamoto
Topics: Ubiquitin and proteasome pathways (106 papers)Protein Degradation and Inhibitors (106 papers)Peptidase Inhibition and Analysis (61 papers)
Cited by: Hematology Oncology Molecular Biology
Journals: Nature Science Cell
Partner nations: United States France United Kingdom

In The Last Decade

Craig M. Crews

204 papers receiving 31.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PROTAC targeted protein degraders: the past is prologue

2022 1.9k citations Craig M. Crews et al. profile →
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

2001 1.8k citations Craig M. Crews et al. Proceedings of the National Academy of Sciences profile →
Induced protein degradation: an emerging drug discovery paradigm

2016 1.1k citations Craig M. Crews et al. profile →
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

2015 849 citations Yimin Qian, Kanak Raina et al. profile →
The Primary Structure of MEK, a Protein Kinase that Phosphorylates the ERK Gene Product

1992 817 citations Craig M. Crews et al. profile →
Epoxomicin, a potent and selective proteasome inhibitor, exhibitsin vivoantiinflammatory activity

1999 803 citations Craig M. Crews et al. Proceedings of the National Academy of Sciences profile →
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

2020 732 citations George M. Burslem, Craig M. Crews profile →
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

2016 661 citations Kanak Raina, Yimin Qian et al. Proceedings of the National Academy of Sciences profile →
Targeted protein degradation: expanding the toolbox

2019 642 citations Craig M. Crews et al. profile →
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

2017 636 citations Daniel P. Bondeson, George M. Burslem et al. Cell chemical biology profile →
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future

2019 555 citations Craig M. Crews et al. profile →
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

1997 530 citations Craig M. Crews et al. Proceedings of the National Academy of Sciences profile →
Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials

2007 525 citations Craig M. Crews et al. profile →
Small‐Molecule PROTACS: New Approaches to Protein Degradation

2016 498 citations Momar Toure, Craig M. Crews profile →
Modular PROTAC Design for the Degradation of Oncogenic BCR‐ABL

2015 492 citations Momar Toure, Saul Jaime‐Figueroa et al. profile →
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

2017 488 citations George M. Burslem, Saul Jaime‐Figueroa et al. Cell chemical biology profile →
PROTACs: past, present and future

2022 463 citations Ke Li, Craig M. Crews profile →
Targeted protein degradation by PROTACs

2017 425 citations Craig M. Crews et al. profile →
Targeted protein degradation: elements of PROTAC design

2019 413 citations Craig M. Crews et al. profile →
Protein degraders enter the clinic — a new approach to cancer therapy

2023 375 citations Deborah Chirnomas, Keith R. Hornberger et al. Nature Reviews Clinical Oncology profile →
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

2019 371 citations Saul Jaime‐Figueroa, Craig M. Crews et al. Nature Communications profile →
PROTACs: An Emerging Therapeutic Modality in Precision Medicine

2020 319 citations Dhanusha A. Nalawansha, Craig M. Crews Cell chemical biology profile →
Targeted Degradation of Oncogenic KRAS ^G12C by VHL-Recruiting PROTACs

2020 313 citations Michael J. Bond, Ling Chu et al. ACS Central Science profile →
Targeted Protein Degradation: from Chemical Biology to Drug Discovery

2017 304 citations Philipp M. Cromm, Craig M. Crews Cell chemical biology profile →
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation

2018 298 citations Momar Toure, Saul Jaime‐Figueroa et al. profile →

Peers

Countries citing papers authored by Craig M. Crews

Since Specialization

Citations

This map shows the geographic impact of Craig M. Crews's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig M. Crews with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig M. Crews more than expected).

Fields of papers citing papers by Craig M. Crews

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig M. Crews. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig M. Crews. The network helps show where Craig M. Crews may publish in the future.

Co-authorship network of co-authors of Craig M. Crews

This figure shows the co-authorship network connecting the top 25 collaborators of Craig M. Crews. A scholar is included among the top collaborators of Craig M. Crews based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig M. Crews. Craig M. Crews is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling 2024 ·Science Advances ·Zhenyi Hu,Po‐Han Chen,(unknown),(unknown),(unknown),Jacques Saarbach,(unknown),John Hines,Yansheng Liu,Craig M. Crews	18
2	Next steps for targeted protein degradation 2024 ·Cell chemical biology ·(unknown),Craig M. Crews	12
3	Protein degraders enter the clinic — a new approach to cancer therapybreakdown → 2023 ·Nature Reviews Clinical Oncology ·Deborah Chirnomas,Keith R. Hornberger,Craig M. Crews	375
4	Mutant-selective degradation by BRAF-targeting PROTACs 2021 ·Nature Communications ·Shanique Alabi,Saul Jaime‐Figueroa,Zhan Yao,Yijun Gao,John Hines,Kusal T. G. Samarasinghe,(unknown),Neal Rosen,Craig M. Crews	105
5	Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras 2021 ·Cell chemical biology ·Kusal T. G. Samarasinghe,Saul Jaime‐Figueroa,Michael Burgess,Dhanusha A. Nalawansha,(unknown),Zhenyi Hu,(unknown),Scott A. Holley,Craig M. Crews	124
6	Targeted Degradation of Oncogenic KRAS ^G12C by VHL-Recruiting PROTACsbreakdown → 2020 ·ACS Central Science ·Michael J. Bond,Ling Chu,Dhanusha A. Nalawansha,Ke Li,Craig M. Crews	313
7	Scaffold hopping enables direct access to more potent PROTACs with in vivo activity 2020 ·Chemical Communications ·George M. Burslem,Daniel P. Bondeson,Craig M. Crews	30
8	Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation 2019 ·Cancer Research ·George M. Burslem,Anna Reister Schultz,Daniel P. Bondeson,Christopher A. Eide,Samantha L. Savage,Brian Druker,Craig M. Crews	165
9	Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs 2019 ·ACS Central Science ·Patrick Pfaff,Kusal T. G. Samarasinghe,Craig M. Crews,Erick M. Carreira	232
10	BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment 2019 ·Journal of Clinical Investigation ·Sujan Piya,Hong Mu,Seemana Bhattacharya,Philip L. Lorenzi,R. Eric Davis,Teresa McQueen,Vivian Ruvolo,Natalia Baran,Zhiqiang Wang,Yimin Qian,Craig M. Crews,Marina Konopleva,Jo Ishizawa,M. James You,Hagop M. Kantarjian,Michael Andreeff,Gautam Borthakur	56
11	Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure–Degradation Relationships 2018 ·ChemMedChem ·George M. Burslem,Philipp Ottis,Saul Jaime‐Figueroa,Alicia Morgan,Philipp M. Cromm,Momar Toure,Craig M. Crews	32
12	Targeted Therapy for AML Expressing RUNX1 Mutation 2017 ·Blood ·Christopher P. Mill,Warren Fiskus,Courtney D. DiNardo,Yimin Qian,Kanak Raina,Koichi Takahashi,Tapan M. Kadia,Dyana T. Saenz,Agnieszka Nowak,Baohua Sun,Craig M. Crews,Kapil N. Bhalla	1
13	Small-Molecule Modulation of Protein Homeostasis 2017 ·Chemical Reviews ·George M. Burslem,Craig M. Crews	220
14	Expeditious Synthesis of Isoquinolones and Isocoumarins with a Vinyl Borane as an Acetylene Equivalent 2016 ·European Journal of Organic Chemistry ·Momar Toure,Saul Jaime‐Figueroa,George M. Burslem,Craig M. Crews	19
15	BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects 2016 ·Blood ·Sujan Piya,Seemana Bhattacharya,Hong Mu,Philip L. Lorenzi,Teresa McQueen,(unknown),Vivian Ruvolo,Natalia Baran,Yimin Qian,Craig M. Crews,Hagop M. Kantarjian,Michael Andreeff,Gautam Borthakur	8
16	Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease 2014 ·Development ·(unknown),Andrew T. Timberlake,(unknown),James R. Monaghan,Craig M. Crews	80
17	Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease 2007 ·Proceedings of the National Academy of Sciences ·Stephanie J. Leuenroth,Dayne Okuhara,(unknown),Glen S. Markowitz,Zhiheng Yu,Stefan Somlo,Craig M. Crews	202
18	Myriaporone 3/4 structure–activity relationship studies define a pharmacophore targeting eukaryotic protein synthesis 2006 ·Molecular BioSystems ·John Hines,Myriam Roy,(unknown),Christina M. Agapakis,Richard E. Taylor,Craig M. Crews	11
19	Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro 2003 ·Journal of Clinical Investigation ·I. Ross Garrett,(unknown),Gabriel Gutiérrez,Ming Zhao,(unknown),G. Rossini,S. E. Harris,(unknown),(unknown),Shihe Hu,Craig M. Crews,Gregory R. Mundy	258
20	The Selective Proteasome Inhibitors Lactacystin and Epoxomicin Can Be Used to Either Up- or Down-Regulate Antigen Presentation at Nontoxic Doses 2000 ·The Journal of Immunology ·Katrin Schwarz,Rita de Giuli,Gunter Schmidtke,Susanne Kostka,Maries van den Broek,Kyung Bo Kim,Craig M. Crews,Regine Kraft,Marcus Groettrup	88

About Craig M. Crews

Craig M. Crews is a scholar working on Oncology, Hematology and Molecular Biology, having authored 209 papers that have together received 32.0k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (106 papers), Protein Degradation and Inhibitors (106 papers) and Peptidase Inhibition and Analysis (61 papers). The work is most often cited by research in Hematology (5.6k citations), Oncology (11.2k citations) and Molecular Biology (27.8k citations). Craig M. Crews has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Raymond L. Erikson, George M. Burslem, Miklós Békés, David R. Langley, John Hines, Momar Toure, Raymond J. Deshaies, Kathleen M. Sakamoto, Alessandro Alessandrini and Timothy W. Corson. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact